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ABSTRACT

ARTICLE HISTORY

Preclinical studies suggest that some effects of conventional chemotherapy, and in particular, gemcita
bine, are mediated through enhanced antitumor immune responses. The objective of this study was to
use material from a randomized clinical trial to evaluate whether patients with preexisting immune
infiltrates responded better to treatment with gemcitabine + docetaxel (GD) compared to docetaxel
alone. Formalin fixed, paraffin-embedded breast cancer tissues from SBG0102 phase 3 trial patients
randomly assigned to treatment with GD or docetaxel were used. Immunohistochemical staining for
CD8, FOXP3, LAG3, PD-1, PD-L1 and CD163 was performed. Tumor infiltrating lymphocytes (TILs) and
tumor associated macrophages were evaluated. Prespecified statistical analyses were performed in
a formal prospective-retrospective design. Time to progression was primary endpoint and overall survival
secondary endpoint. Correlations between biomarker status and endpoints were evaluated using the
Kaplan–Meier method and Cox proportional hazards models. Biomarker data was obtained for 237
patients. There was no difference in treatment effect according to biomarker status for the whole cohort.
In planned subgroup analysis by PAM50 subtype, in non-luminal (basal-like and HER2E) breast cancers
FOXP3 was a significant predictor of treatment effect with GD compared to docetaxel, with a HR of 0.22
(0.09–0.52) for tumors with low FOXP3 compared to HR 0.92 (0.47–1.80) for high FOXP3 TILs (Pinteraction
= 0.01). Immune biomarkers were not predictive of added benefit of gemcitabine in a cohort of mixed
breast cancer subtypes. However, in non-luminal breast cancers, patients with low FOXP3+ TILs may have
significant benefit from added gemcitabine.
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Introduction
Globally, breast carcinoma is the most common malignancy
amongst women and accounts for more than two million new
cases diagnosed each year. Despite targeted treatment options
and the relatively high efficacy of conventional chemotherapy,
breast cancer remains responsible for 15% of all cancer deaths
in women.1 The basal-like/triple-negative (TNBC) subtype of
breast cancer remains the most challenging, as there are cur
rently few treatment options beyond conventional
chemotherapy.12,3
In recent years, the importance of the immune microenvir
onment surrounding cancer cells has gained increasing interest
with the advent of immunotherapy and the discovery of the
significance of an activated immune system for the prognosis
of cancer.4–6 In breast cancer, most research has been centered
around basal-like/TNBC or HER2 positive subtypes, as these
are often characterized by a pronounced inflammatory infil
trate that has shown clear positive prognostic significance.7,8 In
this context, it has been shown that tumor infiltrating
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lymphocytes and particularly the CD8 positive cytotoxic
T-cell subset are important for immune-mediated tumor cell
death.9
PD-L1 inhibitor immune therapy in combination with nabpaclitaxel for advanced TNBC has recently been approved.10,11
However, as breast carcinoma is not one of the most immuno
genic forms of cancer, the search continues for effective
approaches to augment the immune response by priming
tumors for immune therapy.2,12 Conventional chemotherapy
may play a role in this, as several agents have shown relevant
off-target effects on both the innate and adaptive immune
systems.2,13,14 Potentiating effects can be mediated through
immunogenic tumor cell death, changes in IFN-γ and inter
leukin release, novel antigen presentation, and post-treatment
replenishment of the lymphocyte pool with potential replace
ment of regulatory and exhausted phenotype T-cells.2,13,14
Multiple clinical trials have investigated or are investigating
the advantages of adding conventional backbone chemother
apy to immunotherapy; several of these have shown promising
improvements in survival of patients receiving both
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chemotherapy and immunotherapy compared to patients
receiving only monotherapy2,15. Thesignificance of which che
motherapy drug should be combined with immune therapy has
recently been discussed in the context of the Impassion 130
trial combining the PD-L1 inhibitor atezolizumab with nabpaclitaxel,11 and the subsequent Impassion 131 trial combining
atezolizumab with paclitaxel.16 Where the first study led to the
approval of atezolizumab for TNBC, the second trial has not
yet shown significant results. It is a matter for discussion
whether this could be due to a greater use of steroids in the
latter trial as a prerequisite for use with paclitaxel, differences
in the delivery of nab-paclitaxel and paclitaxel in the tumor
microenvironment or even due to TNBC heterogeneity.17
Within TNBC as a category, the immune activated subtype
represents a composition of microenvironments defined by
factors beyond PD-L1 expression that could explain the differ
ences in immunotherapy response between the two trials. In
view of the negative results of the IMpassion-131 trial, it is
currently recommended to use the combination of nabpaclitaxel with atezolizumab in metastatic TNBC.18
Docetaxel and gemcitabine are among the forms of conven
tional cytotoxic chemotherapy that have effects on the tumor
immune microenvironment (TME). In preclinical models,
both drugs induce changes in the TME by modulating innate
and adaptive immune responses, leading to an increased sus
ceptibility to immune mediated cell death.13,19–27 Gemcitabine
in particular seems to enhance T-cell activation in pre-clinical
studies. Changes in the TME following gemcitabine treatment
include inhibition of myeloid-derived suppressor cells, leading
to more activated cytotoxic T-cells, naïve T-cell activation, and
upregulation of natural killer cells along with changes in
macrophage polarization.22,24,28 Clinically, studies have sug
gested that an immune-active environment may predict che
motherapy efficacy including regimes containing taxanes or
gemcitabine.29 However, the predictive capacity of the TME
for benefit from gemcitabine treatment, alone or in combina
tion with docetaxel, has not yet been investigated in a setting
involving randomized clinical trials of breast cancer.
For this study, we used the Danish SBG0102 phase III
clinical trial, which randomized patients with advanced breast
cancer to receive either docetaxel or gemcitabine + docetaxel
(GD). The original trial did not find a survival benefit of GD
over docetaxel alone.30 However, subsequent post-hoc analy
sis using the PAM50 assay showed a large survival advantage
in the GD group amongst patients with basal-like breast
cancer.31 As the basal-like subtype is the most immuneactive intrinsic subtype of breast cancer,32 we investigated
whether the added benefit of gemcitabine, an immunostimu
latory form of chemotherapy, correlated with more active
immune responses in the primary tumor. As biomarkers for
an activated immune response, we assessed CD8 as our pri
mary T-cell marker; stromal tumor infiltrating lymphocytes
(TILs); and immunosuppressive biomarkers including PD-1
(programmed cell death protein 1), PD-L1 (programmed
death ligand 1), LAG3 (lymphocyte activation gene 33),and
FOXP3 (forkhead box protein 3) were also investigated.
Additionally, as a marker for the innate immune system, we
investigated the predictive capacity of CD163 expressing
tumor associated macrophages.

Material and methods
Study population and design
The present study is based on surgical material from patients
enrolled in the Danish Breast Cancer Group (DBCG) rando
mized clinical trial SBG0102. In this trial, patients with locally
advanced or metastatic breast cancer were randomized to
receive either docetaxel or docetaxel + gemcitabine. A total of
337 women were included in the trial. Patients received either
docetaxel (100 mg/m2) on day 1 every 21 days, or gemcitabine
(1000 mg/m2) on days 1 and 8 and docetaxel (75 mg/m2)
on day 8 every 21 days. A detailed description of the study
including eligibility criteria and study results has been pub
lished previously.30 No patients had received neoadjuvant che
motherapy prior to inclusion.
The original study and subsequent supplementary biomar
ker studies were approved by the Danish National Committee
on Biomedical Research Ethics [KF12-315,632 (August 2006)/
H-KF-02-045-01 (June 2007)/H-190131109 (June 2019) with
additional approval 77987 (March 2021)].
The study was designed in accordance with the reporting
recommendations for tumor marker prognostic studies
(REMARK).33 Based on this, our group performed a test of
the prespecified hypothesis that a preexisting immune
response, as defined by the expression of specific immune
response biomarkers in primary breast cancer tumor tissue,
predicts superior time to progression and overall survival in
advanced breast cancer patients, when randomized to
a treatment regime containing both gemcitabine and docetaxel
as compared to (higher dose) docetaxel alone.
As our primary biomarker, we selected CD8 positive intra
tumoral tumor infiltrating lymphocytes (TILs), as this biomar
ker mainly identifies the cytotoxic T-cell subset, shown to be
a major effector of antitumor immune interactions and to carry
prognostic significance in several studies.34–37 For secondary
analyses, we also selected well-described immune checkpoint
molecules including PD-1, PD-L1, and LAG3. FOXP3 was
assessed, as a marker for regulatory T-cells associated with
dampening immune responses.38 Supplementary, CD163,
a macrophage marker, was assessed for predictive capacity.39
Analyses were carried out on the whole cohort, and as
a preselected subgroup analysis on the non-luminal breast
cancers, a category combining the basal-like and HER2enriched (HER2E) PAM50 subtypes based on published
research showing these two subtypes to be similar in their
tumor-immune microenvironment.7,32 Tests for heterogeneity
of prognostic significance in luminal subtypes (luminal A and
luminal B) versus non-luminal subtypes were also performed.
Study material and immunohistochemical staining
In this study, we utilized 11 previously constructed tissue
microarray (TMA) blocks containing formalin fixed, paraffinembedded primary tumor tissue from 276 patients enrolled in
the SBG0102 study, provided by the DBCG Tumor Tissue Data
Repository. The TMAs contain two 2 mm cores of primary
breast cancer tissue per patient, as previously described.40
Immunohistochemical (IHC) staining for CD8 (clone C8/
144B, Dako), PD-1 (clone NAT105, CellMarque), LAG3
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(clone 17B4, Abcam), FOXP3 (clone 236A/E7, Abcam) and
CD163 (clone 10D6, Leica Biosystems) was performed as per
manufacturer’s protocol using the Ventana Discovery Ultra
staining platform at the Genetic Pathology Evaluation Center
(Vancouver, Canada). PD-L1 staining using the SP142 clone
(Roche) was performed following manufacturer’s instructions
at the Victoria Deeley Research Center (Victoria, Canada).
Staining and scoring of the standard breast cancer biomar
kers ER, PR, and HER2 had been performed in connection
with previous publications following published methods at the
Genetic Pathology Evaluation Center, Vancouver, Canada.40–43
Slides were scanned and digitized on the Aperio AT2 scan
ner at 20X magnification. Representative photomicrographs
are shown in supplementary Figure S1.

Biomarker assessment
Biomarker assessment was performed by two experienced
pathologists, DG (CD8, PD-1, FOXP3, LAG3 and CD163)
and ES (TILs and PD-L1). Difficult cases were discussed
between the two pathologists and consensus was reached.
The two pathologists did not have access to clinical data
when scoring the biomarkers.
For CD8, LAG3, PD-1 and FOXP3, scoring data were cap
tured for stromal TILs (sTILs) and intratumoral TILs (iTILS).
As previously published, sTILs were defined as TILs present in
the peritumoral stroma, not in direct contact with carcinoma
cells. iTILs were defined as TILs in direct contact with carci
noma cells. This strategy was chosen as TILs in the intratu
moral and stromal compartment have been shown to exhibit
different prognostic associations.44,45
For CD163, membranous or cytoplasmic expression on
tumor-associated macrophages was scored as previously
described.46
CD8, LAG3, FOXP3 and PD-1 iTILs and sTILs and CD163
positive macrophages were reported as an absolute count in
one TMA core, or in cases where two interpretable cores were
available, the mean of the absolute counts in the two TMA
cores corresponding to each patient. Cutpoints for biomarker
positivity were locked down prior to clinical data analysis. For
CD8, cutpoints that had been previously established and vali
dated on a large cohort were used.44 As the previous cohort
used 0.6 mm cores, cutoffs were expanded by a factor 10 to
account for the increased area of the 2 mm cores used in this
study. For CD8 iTILs, the adjusted cutoffs were ≤10 vs >10; for
CD8 sTILs cutoffs were ≤30 vs >30. For LAG3 and PD-1, we
followed our previous publications on lymphocyte biomarkers
and set cutoffs to dichotomize between no expression and any
expression (0 vs > 0) both for iTILs and sTILs.47,48 FOXP3
iTILs cutoff was set to <2 vs ≥2 and cutoff for FOXP3 sTILs was
<3 vs ≥3.48 The cutoffs for CD163 expressing tumor associated
macrophages were also adjusted from studies in our previous
cohort and were set to <56 vs ≥56.39
PD-L1 scoring was performed according to manufacturer’s
guidelines as area of PD-L1 positive TILs out of total tumor
area.49 A cutoff of ≥1% for positive expression was used when
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relevant, as this is the commonly used cutoff for clinical trials
and treatment indications.10 When relevant, PD-L1 was also
tested as a continuous variable.
TILs were assessed on hematoxylin-eosin (HE) stained slides,
according to the extensively validated guidelines published by
the International Immuno-Oncology Biomarker working
group. Briefly, TILs were scored as the percentage of intratu
moral stroma occupied by lymphocytes.9 The median preva
lence of TILs in our cohort was used as cutoff (≤1% vs >1%).
When relevant, TILs were also tested as a continuous variable.

PAM50 intrinsic subtyping
PAM50 intrinsic subtyping using the Nanostring nCounter
system on the SBG0102 material has been published pre
viously, including a detailed description of RNA extraction,
Nanostring nCounter processing and data analysis.31

Statistical analysis
Statistical analysis was performed by the DBCG according to
a written prespecified plan. Descriptive statistics were utilized
to summarize patient characteristics. Differences in patient
characteristics between biomarker groups were assessed with
chi-squared test or Fishers exact test, excluding unknowns.
As in the original trial, the primary endpoint was time to
progression (TTP) and secondary endpoint overall survival
(OS). TTP was defined as the time from random assign
ment to date of progression with censoring at last visit date
or death. Complete follow-up on vital status data until
July 1st, 2020 was ensured through linkage to the Danish
Civil Registration System (CPR). OS was defined as the
time elapsed from random assignment until death from
any cause.
TTP and OS rates were estimated according to the
Kaplan–Meier method. The effects of the biomarker groups
(low vs. high) and biomarkers as continuous variables per
10%-point increase on TTP and OS were quantified in
terms of hazard ratios (HRs) with 95% confidence intervals
(CI) and estimated unadjusted and adjusted using Cox
proportional hazard models. Biomarkers were assessed indi
vidually, i.e. in separate models.
In multivariate analysis, the following variables were
considered: PAM50 subtype, ECOG performance status
(0–1 vs 2), visceral disease (yes vs no), age (<50 vs ≥ 50),
stage of disease (locally advanced vs metastatic), number of
metastatic sites (<3 vs ≥ 3) and treatment regime. Variables
with statistical significance were included in the final multi
variate models. Tests for proportional hazards were
assessed by Schoenfeld residuals models. The Wald test
for interaction between biomarker expression groups and
subtype (luminal vs non-luminal) or treatment arm was
used to evaluate differences between subgroups and predic
tive effects, respectively.
All tests were two-sided with a significance level of 0.05,
unadjusted for number of comparisons.
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All statistical analyses were performed with the use of SAS
software, version 9.4 (SAS Institute, Cary, NC, USA).

Results
Clinicopathological characteristics and biomarker
expression
Biomarker assessment was available in 237 out of the 276
patients with TMA available. In 39 cases, biomarker assess
ment was not possible due to insufficient tissue remaining in
the core, or too few invasive breast cancer cells present. Out of
the 237 patients, IHC assessment of CD8 was possible in 234
cases, 233 cases for FOXP3, 230 cases for LAG3, 231 cases for
PD-1, 219 cases for PD-L1 and 224 cases for CD163. TIL
evaluation on HE slides was possible in 216 cases. Out of the
237 patients with IHC scores, 5 patients did not have PAM50
information available. A flow diagram of the study cohort is
presented in Supplementary Figure S2.
The group of patients available for biomarker assessment
differed from the excluded group wwith regard toprior che
motherapy regimens (anthracyclines vs non-anthracyclines)
and radiotherapy (P < .05) (data not shown). This is most likely
due to patients with locally advanced disease, as these patients
more often only had a needle biopsy available for testing,
resulting in tissue being unavailable or with too few tumor
cells for testing. The excluded group did not differ from the
included group in other parameters. Patient characteristics
according to treatment allocation have been previously
described for the whole cohort30 and can be seen in
Supplementary Table S1 for the cohort used in this study.
We found high CD8 iTIL expression in a total of 80 patients
(34%); the median absolute count was 7 per 2 mm tissue core.
High CD8 sTIL expression was seen in 182 patients (78%) with
a median of 100. Patient characteristics according to CD8 iTILs
can be seen in Supplementary Table S3. Neither CD8 iTIL nor
sTIL expression were significantly associated with the subtype
(Table 1) or hormone receptor status (Supplementary Table
S3) in this data set of primary tumor tissue samples from
patients who developed advanced disease. CD8 positivity was
also not associated with any other relevant clinicopathological
characteristics.
Median absolute counts per core were 1 for FOXP3 iTILs,
12 for FOXP3 sTILs, and 0 for LAG3 and PD-1 (iTILs or

sTILs). Median PD-L1 expression was 0, and median HE
TILs were 1%. Median CD163 positive cell count (macro
phages) was 46. Associations of biomarkers with PAM50 sub
types are presented in Table 1. Expression of FOXP3, LAG3,
PD-1, PD-L1, and HE TIL counts were all associated with
PAM50 subtypes (P < .05). For all of them, a higher percentage
of positive expression was seen in the basal-like and HER2
enriched subtypes. PD-1, LAG3 and FOXP3 iTILs were also
associated with ER negativity (data not shown).
For the whole cohort, total number of events were 231 for
OS and 176 for TTP. For the non-luminal subtypes (basal-like
+ HER2E), there were 74 events for OS and 59 events for TTP.
In multivariate analysis of the study, PAM50 subtype,
ECOG performance status (0–1 vs 2) and visceral disease (yes
vs. no) were found to be significant for OS. Treatment with
combination therapy (GD) was associated with significantly
longer TTP compared to monotherapy with docetaxel.
Likewise, PAM50 subtypes were significantly associated with
TTP. Hazard ratios for all significant variables are presented in
Supplementary Table S2.
Prognostic value of immune biomarkers in SBG0102
advanced breast cancers
In the whole cohort, CD8 iTILs were not prognostic for either
TTP or OS in uni- or multivariate analysis (Table 2, Figure 1a
and b, Supplementary Figure S3, A-B and Supplementary Table
S4). In a test of heterogeneity for differential effect in the
luminal and non-luminal subtypes (basal like and HER2E
together, 76 patients), there was a lower HR for OS for the
CD8 iTILs high group in univariate analysis (HR 0.69 [95%CI
0.43–1.11], vs HR 1.28 [0.91–1.81] for luminal cases, Pinteraction
= 0.04). This was not preserved in multivariate analysis (0.70
[0.43–1.13] vs HR 1.21 [0.84–1.74], Pinteraction = 0.08)
(Supplementary Table S5).
While we had chosen intratumoral TILs as our primary
mode of assessment of CD8 as we had in other studies,44,50
stromal CD8+ TILs were also assessed. CD8 sTILs did not
show prognostic significance for the whole cohort. However,
in a test of heterogeneity of effect in the luminal and nonlum
inal subtypes, there was also a trend toward a lower HR for
TTP in the CD8 sTILs high non-luminal subtypes than in the
CD8 sTILs high luminal subtypes (HR 0.46 [0.24–0.86] for
non-luminal subtypes vs HR 1.00 [0.63–1.58] for luminal

Table 1. Correlations of investigated biomarkers with PAM50 subtypes (n = 232).
Total [n (%)]
Biomarker
CD8 iTILs count ≤10 vs >10
CD8 sTILs count ≤30 vs >30
FOXP3 iTILs count <2 vs ≥2
FOXP3 sTILs count <3 vs ≥3
LAG3 iTILs count 0 vs ≥1
LAG3 sTILs count 0 vs ≥1
PD-1 iTILs count 0 vs ≥1
PD-1 sTILs count 0 vs ≥1
PD-L1 < 1% vs ≥1%
HE TILs ≤1% vs >1%
CD163 TAM <56 vs ≥56

Low
150 (66)
51 (22)
132 (58)
58 (26)
188 (84)
143 (64)
181 (80)
127 (56)
185 (87)
135 (64)
132(46.5)

High
79 (34)
178 (78)
95 (42)
169 (74)
37 (16)
82 (36)
45 (20)
99 (44)
28 (13)
76 (36)
92 (32.4)

Luminal A [n (%)]
Low
54 (76)
13 (18)
54 (77)
29 (41)
66 (96)
57 (83)
63 (91)
44 (64)
63 (98)
45 (71)
41(63.1)

High
17 (24)
58 (82)
16 (23)
41 (59)
3 (4)
12 (17)
6 (9)
25 (36)
1 (2)
18 (29)
24 (36.9)

Luminal B [n (%)]
Low
51 (62)
21 (26)
47 (58)
21 (26)
71 (89)
52 (65)
65 (79)
54 (66)
66 (88)
55 (71)
58(73.4)

High
31 (38)
61 (74)
34 (42)
60 (74)
9 (11)
28 (35)
17 (21)
28 (34)
9 (12)
22 (29)
21 (26.6)

Basal like [n (%)]
Low
17 (52)
9 (27)
9 (27)
3 (9)
18 (55)
13 (39)
20 (63)
10 (31)
22 (69)
15 (49)
6(18.8)

High
16 (48)
24 (73)
24 (73)
30 (91)
15 (45)
20 (61)
12 (38)
22 (69)
10 (31)
17 (53)
26 (81.2)

HER2E [n (%)]
Low
28 (65)
8 (19)
22 (51)
5 (12)
33(77)
21 (49)
33 (77)
19 (44)
34 (81)
20 (51)
23 (59)

High
15 (35)
35 (81)
21 (49)
38 (88)
10 (23)
22 (51)
10 (23)
24 (56)
8 (10)
19 (49)
16 (41)

P
0.08
0.58
<0.0001
0.0004
<0.0001
<0.0001
0.007
0.002
0.0004
0.02
<0.001

Numbers of patients are shown and percentages of the given subtype in parentheses. Cases with missing biomarker scores not shown. iTILs: intratumoral tumor
infiltrating lymphocytes, sTILs: stromal tumor infiltrating lymphocytes, HE: hematoxylin-eosin; TAM: tumor associated macrophages.
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Table 2. Prognostic hazard ratios in the overall cohort for high vs low levels of
immune biomarkers in univariate analysis.
HR (95% CI)
Biomarker (High vs Low)
CD8 iTILs count ≤10 vs >10
CD8 sTILs count ≤30 vs >30
FOXP3 iTILs count <2 vs ≥2
FOXP3 sTILs count <3 vs ≥3
LAG3 iTILs count 0 vs ≥1
LAG3 sTILs count 0 vs ≥1
PD-1 iTILs count 0 vs ≥1
PD-1 sTILs count 0 vs ≥1
PD-L1 < 1% vs ≥1%
HE TILs ≤1% vs >1%

TTP
1.04 (0.76–1.43)
0.86 (0.60–1.24)
0.99 (0.74–1.34)
0.90 (0.64–1.25)
1.42 (0.95–2.14)
1.22 (0.89–1.67)
1.39 (0.97–1.96)
1.17 (0.87–1.57)
1.59 (1.03–2.44)
1.06 (0.78–1.45)

P
0.81
0.43
0.96
0.52
0.09
0.21
0.07
0.31
0.04
0.71

OS
1.10 (0.83–1.44)
1.00 (0.73–1.37)
1.21 (0.93–1.58)
1.00 (0.74–1.34)
1.28 (0.90–1.82)
1.46 (1.11–1.93)
1.04 (0.75–1.45)
0.93 (0.71–1.21)
1.47 (0.98–2.20)
1.03 (0.78–1.37)

P
0.51
0.99
0.15
0.97
0.17
0.01
0.80
0.58
0.06
0.82

Abbreviations: HR: hazard ratio, TTP: time to progression, OS: overall survival, iTILs:
intratumoral tumor infiltrating lymphocytes, sTILs: stromal tumor infiltrating
lymphocytes, HE: hematoxylin-eosin.

subtypes, Pinteraction = 0.06) in univariate analysis. The same
was seen in multivariate analysis (Supplementary Table S5).
CD8 sTILs also showed a trend for improved OS in the nonluminal subtypes in univariate analysis, although this was not
significant (HR 0.65 [0.38–1.12]) (Supplementary Figure S4) .
FOXP3 iTILs, PD-1, LAG3 iTILs and HE TILs also did not
show prognostic significance when looking at the whole cohort
in univariate analysis (Table 2). LAG3 sTILs did show prog
nostic significance for OS in univariate analysis (HR 1.46 [1.
11–1.93]), and PD-L1 high expression was significant for TTP
in univariate analysis (HR 1.59 [1.03–2.44]); however, these
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effects were not retained in multivariate analysis
(Supplementary Table S4). FOXP3 sTILs were not significant
for TTP in univariate analysis; however, in multivariate analy
sis including PAM50 subtypes and treatment regime, high
FOXP3 sTILs were significant for TTP (HR 0.67 [0.46–0.98],
P = .04). This was mainly driven by adjustment for PAM50
subtypes (TTP for LAG3 iTILs when only adjusted for PAM50
subtypes: HR: 0.63 [0.44–0.93]; TTP when only adjusted for
treatment HR 0.93 [0.66–1.31]).
In the planned subgroup analysis of the non-luminal and
luminal subtypes, FOXP3, PD-1, PD-L1, LAG3 and HE TILs
did not impact survival in either uni- or multivariate analysis,
and there was no differential effect in luminal and non-luminal
subtypes (Supplementary Table S5).

Predictive value of immune biomarkers for gemcitabine +
docetaxel vs. docetaxel monotherapy
There were no significant differences in treatment effect
according to CD8 iTIL status for patients treated with doce
taxel or GD for the primary endpoint of TTP or the secondary
endpoint of OS (Figure 1c and d, Table 3).
For CD163, there were no significant differences for TTP
(Table 3). However, patients with high expression benefitted
significantly more from GD than from docetaxel in univariate
analysis of OS (HR for low expression 1.16 [CI:0.81–1.65], HR

Figure 1. Time to progression (TTP) and associations with CD8 levels in the SBG0102 trial population. A. CD8 iTILs and TTP in the overall cohort, B. CD8iTILs and TTP in
the non-luminal (BL and HER2E) subtypes C. TTP for the CD8 iTILs low group, stratified by treatment with docetaxel or docetaxel +gemcitabine (DG) D. TTP for the CD8
iTILs high group, stratified by treatment with docetaxel or DG. Corresponding figures for overall survival can beseen in Supplementary Figure S3. iTILs: intratumoral
tumor infiltrating lymphocytes.
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Table 3. Predictive hazard ratios for treatment effect for TTP in patients treated with docetaxel + gemcitabine vs docetaxel alone. Values shown for multivariate analysis
for the whole subset, and for the focused set of analyses performed on the non-luminal subset a Basal like + HER2E.
Non-luminal subseta

Whole cohort

HR (95% CI)

HR (95% CI)
Biomarker
CD8 iTILs count ≤10 vs >10
CD8 sTILs count ≤30 vs >30
FOXP3 iTILs count <2 vs ≥2
FOXP3 sTILs count <3 vs ≥3
LAG3 iTILs count 0 vs ≥1
LAG3 sTILs count 0 vs ≥1
PD-1 iTILs count 0 vs ≥1
PD-1 sTILs count 0 vs ≥1
PD-L1 < 1% vs ≥1%
HE TILs ≤1% vs >1%
CD163 TAM <56 vs ≥56

Low
0.71 (0.49–1.02)
0.80 (0.45–1.40)
0.59 (0.39–0.89)
0.76 (0.41–1.40)
0.69 (0.50–0.96)
0.71 (0.48–1.04)
0.68 (0.48–0.96)
0.75 (0.49–1.14)
0.68 (0.48–0.95)
0.66 (0.45–0.98)
0.72 (0.47–1.10)

High
0.73 (0.43–1.22)
0.70 (0.51–0.96)
0.88 (0.56–1.38)
0.72 (0.51–1.02)
0.77 (0.37–1.63)
0.69 (0.42–1.13)
0.88 (0.47–1.67)
0.66 (0.42–1.02)
0.85 (0.39–1.88)
0.90 (0.54–1.48)
0.51 (0.32–0.83)

Pinteraction
0.93
0.79
0.21
0.87
0.79
0.96
0.48
0.66
0.60
0.35
0.30

Low
0.42 (0.21–0.81)
0.31 (0.10–1.02)
0.22 (0.09–0.52)

High
0.76 (0.33–1.74)
0.63 (0.35–1.13)
0.92 (0.47–1.80)

Pinteraction
0.27
0.29
0.01

0.39 (0.16–0.93)

0.64 (0.32–1.30)

0.38

Abbreviations: HR: hazard ratio, TTP: time to progression, iTILs: intratumoral tumor infiltrating lymphocytes, sTILs: stromal tumor infiltrating lymphocytes, HE:
hematoxylin-eosin, TAM: tumor associated macrophages.

for high expression 0.63 [0.41–0.96], Pinteraction = 0.03).
However, this effect was not significant in multivariate analysis
(HR for low expression 1.09 [CI:0.76–1.58], HR for high
expression 0.62 [0.40–0.96], Pinteraction = 0.051)
None of the other biomarkers investigated were predictive
of treatment effect when looking at the whole cohort (see Table
3 and Figure 2a and b).
We also performed subgroup analyses of CD8 iTILs and
sTILs, FOXP3 iTILs and CD163 in the non-luminal subtypes
(basal + HER2E). Low FOXP3 iTILs were found to benefit
significantly more from GD than from docetaxel alone with
aanHR of 0.22 (CI: 0.09–0.52) for low FOXP3 iTILs compared
to HR 0.92 (CI: 0.47–1.80) for high FOXP3 iTILs (Pinteraction
= 0.01) for TTP (Figure 2c and d, Supplementary Figure S5).
CD8 status and CD163 were not predictive in the non-luminal
subgroup analysis.

Discussion
In the SBG0102 clinical trial randomizing patients with
advanced breast cancer to receive either docetaxel or docetaxel
+ gemcitabine, we found that CD8 positive TILs were not
prognostic for the overall cohort but did show some prognostic
significance in the non-luminal subtypes. These results align
well with what we expected, as TILs in ER positive subtypes do
not carry prognostic significance to the same degree as they do
in the ER negative subset.51 CD8 TILs and our other biomar
kers of adaptive immunity also did not have predictive value
for benefit from gemcitabine in the whole cohort. The macro
phage marker CD163 did give some indication of a possible
significant predictive effect for OS. Studies have shown that
docetaxel and gemcitabine modulate the innate immune sys
tem including macrophages and myeloid-derived suppressor
cells in both stimulatory and inhibitory ways.19,20,24 Taken
together with results of our study, further research on the
predictive capacity of markers of the innate immune system
is warranted in prospective cohorts treated with immune mod
ulating chemotherapies.

In the subgroup analysis of the non-luminal subtypes, where
the degree of immune response should be most significant for
outcome, we also found that CD8 TILs were not predictive for
benefit from gemcitabine. In this group, we did, however, find
that patients with low FOXP3 levels benefitted more from GD
than from docetaxel alone. The FOXP3 positive subset of
T-lymphocytes are also known as regulatory T-cells, and func
tion as negative regulators of CD8 positive cytotoxic T-cells,
thereby contributing to a dampening of the immune response
to tumor cells. Some chemotherapeutic drugs have been shown
to specifically deplete regulatory T-cells,28,52 so in patients with
already low levels of FOXP3 regulatory T-cells, this might
mean that the inhibitory effect of these cells could become
almost totally removed. Our results could signify that patients
with low levels of regulatory T-cells do benefit from the addi
tion of another chemotherapeutic drug that contributes to a net
immunostimulatory effect. However, events were few in this
exploratory analysis and our results should be tested in a larger
cohort. Although most studies on the effect of docetaxel and
gemcitabine on the TME have shown a stimulating effect, some
pre-clinical studies have instead shown a detrimental effect on
the efficacy of immune eradication of cancer cells with treat
ment with either docetaxel or gemcitabine. Debangshu eet al.
showed that treatment with taxanes induced the T-cell inhibi
tory biomarkers PD-L1 and CD73 and macrophage inhibiting
CD47 on breast cancer cells.53 An inhibitory effect on natural
killer cells by docetaxel has also been shown.54 One possible
explanation for our inability to identify a benefit from gemci
tabine in tumors with CD8 high expression is that cotreatment with docetaxel may have canceled out any immune
stimulatory effects.
Nevertheless, giving taxanes together with immunotherapy
has already been shown to benefit the TNBC subset of patients
and seems to be more beneficial than giving immunotherapy
alone. The Impassion 130 trial, which led to FDA-approval of
the PD-L1 inhibitor atezolizumab, combined nab-paclitaxel
with atezolizumab, for first-line treatment of unresectable,
locally advanced or metastatic breast cancer patients. This
study has reported improved survival in the PD-L1 positive
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Figure 2. Time to progression (TTP) and associations with FOXP-3 iTILs levels and treatment arm in the SBG0102 trial population (A+B) and in the nonluminalsubtypes (C
+D). A. TTP for the FOXP3 iTILs low group, stratified by treatment with docetaxel or docetaxel + gemcitabine (DG), B. TTP for theFOXP3 iTILs high group, stratified by
treatment with docetaxel or docetaxel + gemcitabine, C. TTP for the FOXP3 iTILs low non-luminal group, stratifiedby treatment with docetaxel or docetaxel +
gemcitabine. D. TTP for the FOXP3 iTILs high non-luminal group, stratified by treatment with docetaxel orDG. Corresponding figures for overall survival can be seen in
Supplementary Figure S4. iTILs: intratumoral tumor infiltrating lymphocytes.

group of patients. There are several ongoing trials combining
docetaxel or paclitaxel with other immune therapies and in
combination with one or more other chemotherapy options
(clinicaltrials.gov:
NCT03639948,
NCT00179309,
NCT03894007)).[2,55,56] It is, however, important to note that
the Impassion 131 trial, treating metastatic TNBC with atezo
lizumab and paclitaxel as first-line treatment, has not yet
shown a benefit of adding atezolizumab. The Impassion 131
trial was done in a patient population quite similar to that in
Impassion 130, but with a different study design and using
paclitaxel instead of nab-paclitaxel.16
There are also several trials underway using regimens con
taining gemcitabine in combination with checkpoint inhibitors
and other chemotherapy treatments.2,55 However, our results
suggest that a addition of a second chemotherapy drug may not
translate into clinical benefit despite presence of
a demonstrable tumor immune reaction. This may be an
important consideration for planning future trials, as patients
may be spared from treatment with several different che
motherapies given in addition to immune therapy.
Strengths and limitations
Strengths of our study include use of material from
a randomized clinical trial, a prespecified statistical plan,
and validated biomarkers with prespecified cut-points in
a formal prospective-retrospective design. However, our

study also has important limitations. Our tumor material
originated from the primary surgery of the patients, but the
study intervention happened in the advanced setting, after
patients had received systemic treatment and radiotherapy.
Our study did not include tissue from the recurrences or
metastases. Studies have shown that hormone receptors and
HER2 status may change between primary tumors and their
subsequent metastases.57 The biological and clinical signifi
cance of receptor conversion in the context of the TME is
not known. Heterogeneity may exist between the immune
profiles of the primary and metastatic lesions and charac
terization of metastatic lesions may provide insights for
guiding the course of systemic therapies.58 However, studies
including biopsies of primary and matched metastatic sites
have shown that though the absolute lymphocyte counts
may decline in the latter lesions, the distribution of T and
B cell subsets in metastatic sites closely approximate that of
the primary tumor. These observations suggest that the
primary tumor may in fact drive the immune cell niche
in metastatic sites.59–62 From a clinical perspective, it is
important to note that the biomarker study on IMpassion130 trial samples demonstrated that despite lower preva
lence of PD-L1 in metastatic samples, there was no differ
ence in the treatment efficacy with respect to biomarker
expression in the primary or metastatic sites.62 However,
further prospective, validation studies with clinical outcome
are warranted.
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Contrary to the original trial from which the material used
in this study was taken, there was a significant benefit of GD vs
D for the overall cohort (Supplementary Table S2). However,
the difference in treatment effect is most likely random, and
survival estimates differ only slightly from the original study.30
Our study included all intrinsic breast cancer subtypes and
was not powered to investigate the basal-like + CD8 high group
alone, the group that would probably be the most likely to show
prognostic significance of immune-related biomarkers. This
was further supported by our finding that FOXP3 sTILs did
have prognostic significance when adjusted for all four PAM50
subtypes, but not when looking at the combined non-luminal
subtypes HER2E and basal-like together.
For evaluation of biomarkers, we chose to distinguish
between lymphocytes in the peritumoral stroma and intratu
moral lymphocytes. Evaluation of stromal TILs is standard
when evaluating TILs on HHE-stainedslides, mainly because
(blue) lymphocytes are easier to identify against a (pink)
stromal background than against a (blue) carcinoma cell
background,
leading
to
increased
interobserver
reproducibility.63 We chose CD8 iTILs as our primary bio
marker as, from a biological standpoint, TILs that are in
direct contact with tumor cells should be the most significant
in the tumor-cytotoxic immune cell interaction, and immu
nohistochemically brown-stained intratumoral TILs are read
ily identifiable within carcinoma cell nests. However, we
found in our study that CD8 sTILs, present in greater num
bers and in a greater fraction of cases than iTILs, were
significantly prognostic for our primary endpoint of TTP,
whereas CD8 iTILs were not. The best method for evaluating
TILs immunohistochemically remains controversial, and it is
possible that we made a suboptimal choice of primary
biomarker.
Finally, we used TMAs in our study. Advantages of TMAs
are that a large number of tumor samples can be stained for
biomarkers under very similar conditions, ensuring a uniform
technical result. Also, evaluation can be more standardized
when looking at smaller sections of tumor, than when looking
at a whole tumor slide. Disadvantages of TMAs relate mainly to
only looking at a very small section of tumor, which can be an
issue if biomarkers are heterogeneously expressed. In our
sstudy,we used duplicate 2 mm cores, which increase the area
investigated somewhat from the more commonly used 0.6 mm
or 1 mm cores.

Conclusion
Evidence suggests that effects of conventional chemotherapy
are, in part, mediated through modulation of the tumor
microenvironment. Gemcitabine in particular has been
shown to affect specific immune cell types in the tumor
microenvironment, raising the hypothesis that the degree
and type of inflammation could be predictive of treatment
effect. Using a formal prospective-retrospective study design,
we tested this in material from a clinical trial that randomized
patients to docetaxel or docetaxel + gemcitabine. For our
biomarkers tied to cytotoxic T-cell immune response, we
did not find that levels of our primary biomarker (CD8+ intra
tumoral T-cells) were predictive of treatment response. Only

in a subgroup analysis of FOXP3+ lymphocytes in nonluminal breast cancers was a significant predictive effect
observed. CD163, a marker of the innate immune system
showed borderline significance, indicating that further studies
investigating predictive capacity of the innate immune system
are warranted. Overall, our results imply that adding several
types of immune stimulating conventional chemotherapy
may not enhance immune benefits. These results may be
significant for future immunotherapy trials combining one
or more conventional types of chemotherapy with immune
therapy.

Acknowledgments
This study was supported by the Canadian Cancer Society (grant number
#705463), Kristian and Margrethe Kjaer Foundation, Else and Mogens
Wedell-Wedellsborg Foundation and Emil and Inger Hertz Foundation.
K. Asleh is supported by the Vanier Canada Graduate Scholarship –
Canadian institutes of Health Research.

Disclosure
ES Stovgaard, K Asleh, D Nielsen, E Balslev, N Riaz, S Leung,
A-V Lænkholm, D Gao, LB Nielsen, declare no conflicts of interest. TO
Nielsen declares a proprietary interest in the Prosigna assay for PAM50
intrinsic subtyping. M-B Jensen has received institutional funding from
Nanostring Technologies within the past two years.

Funding
This work was supported by the Canadian Cancer Society [705463]; Else
og Mogens Wedell Wedellsborgs Fond [x]; Købmand M. Kristjan Kjær og
Hustru Margrethe Kjær, Født la Cour-Holmes Fond [x]; Vanier Canada
Graduate Scholarship- Canadian Institutes of Health Research [x];
Direktør Emil Hertz og Hustru Inger Hertz Fond [x].

ORCID
Elisabeth S Stovgaard

http://orcid.org/0000-0002-5784-3610

References
1. WHO. Breast cancer [Internet]. [accessed 2020 Oct 20]. https://
www.who.int/cancer/prevention/diagnosis-screening/breastcancer/en/ .
2. Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative
breast cancer. JNCCN J Natl Compr Cancer Netw. 2020;18
(4):479–489. doi:10.6004/jnccn.2020.7554.
3. Pouptsis A, Swafe L, Patwardhan M. Surgical and systemic treat
ment of hereditary breast cancer: a mini-review with a focus on
BRCA1 and BRCA2 mutations. Front Oncol. 2020;10:553080.
doi:10.3389/fonc.2020.553080.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next
generation.
Cell.
2011;144(5):646–674.
doi:10.1016/j.
cell.2011.02.013.
5. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D,
Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic land
scape of genes and infiltrating immune cells across human cancers.
Nat Med. 2015;21(8):938–945. doi:10.1038/nm.3909.
6. Emens LA. Breast cancer immunotherapy: facts and hopes. Clin
Cancer Res. 2018;24(3):511–520. doi:10.1158/1078-0432.CCR-163001.
7. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D,
Kellokumpu-Lehtinen P-L, Bono P, Kataja V, Desmedt C, et al.

ONCOIMMUNOLOGY

8.

9.

10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

Tumor infiltrating lymphocytes are prognostic in triple negative
breast cancer and predictive for trastuzumab benefit in early breast
cancer: results from the FinHER trial. Ann Oncol. 2014;25
(8):1544–1550. doi:10.1093/annonc/mdu112.
Gao G, Wang Z, Qu X. Prognostic value of tumor-infiltrating
lymphocytes in patients with triple-negative breast cancer:
a systematic review and meta-analysis. BMC Cancer. 2020;20
(1):179. doi:10.1186/s12885-020-6668-z.
Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F,
Pruneri G, Wienert S, Van Den Eynden G, Baehner FL, PenaultLlorca F, et al. The evaluation of tumor-infiltrating lymphocytes
(TILs) in breast cancer: recommendations by an International TILs
working group 2014. Ann Oncol. 2015;26(2):259–271.
Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E,
Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO,
Lænkholm A-V, et al. The path to a better biomarker: application
of a risk management framework for the implementation of PD-L1
and TILs as immuno-oncology biomarkers in breast cancer clinical
trials and daily practice. J Pathol. 2020;250(5):667–684.
doi:10.1002/path.5406.
Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH,
Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, et al.
Atezolizumab plus nab-paclitaxel as first-line treatment for unre
sectable, locally advanced or metastatic triple-negative breast can
cer (IMpassion130): updated efficacy results from a randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet Oncol.
2020;21(1):44–59. doi:10.1016/S1470-2045(19)30689-8.
Hamilton G. Avelumab: search for combinations of immune
checkpoint inhibition with chemotherapy. Expert Opin Biol Ther.
2020;21:1–12.
Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K-Y, Ferrone S,
Gameiro SR. Chemotherapy-induced immunogenic modulation of
tumor cells enhances killing by cytotoxic T lymphocytes and is
distinct from immunogenic cell death. Int J Cancer. 2013;133
(3):624–636. doi:10.1002/ijc.28070.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, Van De
Vijver KK, De Maaker M, Nederlof I, Kluin RJC, Warren S,
Ong S, et al. Immune induction strategies in metastatic
triple-negative breast cancer to enhance the sensitivity to PD-1
blockade: the TONIC trial. Nat Med. 2019;25(6):920–928.
doi:10.1038/s41591-019-0432-4.
Shaikh SS, Emens LA. Current and emerging biologic therapies for
triple negative breast cancer. Expert Opin Biol Ther. 2020;1–12.
doi:10.1080/14712598.2020.1801627.
Primary results from IMpassion131, a double-blind placebocontrolled randomised phase III trial of first-line paclitaxel (PAC)
± atezolizumab (atez . . . | oncologyPRO. [accessed 2020 Dec 10].
https://oncologypro.esmo.org/meeting-resources/esmo-virtualcongress-2020/primary-results-from-impassion131-a-doubleblind-placebo-controlled-randomised-phase-iii-trial-of-first-linepaclitaxel-pac-atezolizumab-atez .
Burstein MD, Tsimelzon A, Poage GM, Covington KR,
Contreras A, Fuqua SAW, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al. Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 2015;21(7):1688–1698. doi:10.1158/
1078-0432.CCR-14-0432.
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS,
André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, et al.
5th ESO-ESMO international consensus guidelines for advanced
breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649.
doi:10.1016/j.annonc.2020.09.010.
Mu XY, Wang RJ, Yao ZX, Zheng Z, Jiang J-T, Tan M-Y, Sun F,
Fan J, Wang X, Zheng J-H, et al. RS 504393 inhibits M-MDSCs
recruiting in immune microenvironment of bladder cancer after
gemcitabine treatment. Mol Immunol. 2019;109:140–148.
doi:10.1016/j.molimm.2019.02.014.
Zhang Y, Bush X, Yan B. Gemcitabine nanoparticles promote
antitumor
immunity
against
melanoma.
Biomaterials
2019;189:48–59. doi:10.1016/j.biomaterials.2018.10.022.

e1924492-9

21. Gravett AM, Trautwein N, Stevanović S, Copier J. Gemcitabine
alters the proteasome composition and immunopeptidome of
tumour
cells.
Oncoimmunology.
2018;7(6):e1438107.
doi:10.1080/2162402X.2018.1438107.
22. Zhang X, Wang D, Li Z, Jiao D, Jin L, Cong J, Zheng X, Xu L. Lowdose gemcitabine treatment enhances immunogenicity and natural
killer cell-driven tumor immunity in lung cancer. Front Immunol.
2020;11:331. doi:10.3389/fimmu.2020.00331.
23. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY.
A novel chemoimmunomodulating property of docetaxel: suppres
sion of myeloid-derived suppressor cells in tumor bearers. Clin
Cancer Res. 2010;16(18):4583–4594. doi:10.1158/1078-0432.CCR10-0733.
24. Millrud CR, Mehmeti M, Leandersson K. Docetaxel pro
motes the generation of anti-tumorigenic human
macrophages.
Exp
Cell
Res.
2018;362(2):525–531.
doi:10.1016/j.yexcr.2017.12.018.
25. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and
recombinant vaccine enhances T-cell responses and antitumor
activity: effects of docetaxel on immune enhancement. Clin
Cancer Res. 2008;14(11):3536–3544. doi:10.1158/1078-0432.CCR07-4025.
26. D’Costa Z, Jones K, Azad A, Van Stiphout R, Lim SY, Gomes AL,
Kinchesh P, Smart SC, Gillies Mckenna W, Buffa FM, et al.
Gemcitabine-induced TIMP1 attenuates therapy response and
promotes tumor growth and liver metastasis in pancreatic cancer.
Cancer Res. 2017;77(21):5952–5962. doi:10.1158/0008-5472.CAN16-2833.
27. Bulle A, Dekervel J, Deschuttere L, Nittner D, Libbrecht L, Janky R,
Plaisance S, Topal B, Coosemans A, Lambrechts D, et al.
Gemcitabine recruits M2-type tumor-associated macrophages
into the stroma of pancreatic cancer. Transl Oncol. 2020;13
(3):100743. doi:10.1016/j.tranon.2020.01.004.
28. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M,
Chevriaux A, Martin F, Apetoh L, Rébé C, Ghiringhelli F, et al.
5-Fluorouracil selectively kills tumor-associated myeloid-derived
suppressor cells resulting in enhanced T cell-dependent antitumor
immunity. Cancer Res. 2010;70(8):3052–3061. doi:10.1158/00085472.CAN-09-3690.
29. Opzoomer JW, Sosnowska D, Anstee JE, Spicer JF, Arnold JN.
Cytotoxic chemotherapy as an immune stimulus: a molecular per
spective on turning up the immunological heat on cancer. Front
Immunol. 2019;10:1654. doi:10.3389/fimmu.2019.01654.
30. Nielsen DL, Bjerre KD, Jakobsen EH, Cold S, Stenbygaard L,
Sørensen PG, Kamby C, Møller S, Jørgensen CLT, Andersson M,
et al. Gemcitabine plus docetaxel versus docetaxel in patients with
predominantly human epidermal growth factor receptor
2-negative locally advanced or metastatic breast cancer:
a randomized, phase III study by the Danish breast cancer coop
erative group. J Clin Oncol. 2011;29(36):4748–4754. doi:10.1200/
JCO.2010.33.9507.
31. Jorgensen CLT, Nielsen TO, Bjerre KD, Liu S, Wallden B,
Balslev E, Nielsen DL, Ejlertsen B. PAM50 breast cancer intrin
sic subtypes and effect of gemcitabine in advanced breast can
cer patients. Acta Oncol. 2014;53(6):776–787. doi:10.3109/
0284186X.2013.865076.
32. Burugu S, Asleh-Aburaya K, Nielsen TO. Immune infiltrates in the
breast cancer microenvironment: detection, characterization and
clinical implication. Breast Cancer. 2017;24(1):3–15. doi:10.1007/
s12282-016-0698-z.
33. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M,
Clark GM. Reporting recommendations for tumor marker prog
nostic studies (REMARK). J Natl Cancer Inst. 2005;97
(16):1180–1184. doi:10.1093/jnci/dji237.
34. Stanton SE, Disis ML. Clinical significance of tumor-infiltrating
lymphocytes in breast cancer. J Immunother Cancer. 2016;4(1):59.
doi:10.1186/s40425-016-0165-6.
35. Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G,
Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S,
et al. Immune characterization of breast cancer metastases:

e1924492-10

36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.

47.

48.

E. S. STOVGAARD ET AL.

prognostic implications. Breast Cancer Res. 2018;20(1):62.
doi:10.1186/s13058-018-1003-1.
Koganemaru S, Inoshita N, Miura Y, Miyama Y, Fukui Y, Ozaki Y,
Tomizawa K, Hanaoka Y, Toda S, Suyama K, et al. Prognostic value
of programmed death-ligand 1 expression in patients with stage III
colorectal cancer. Cancer Sci. 2017;108(5):853–858. doi:10.1111/
cas.13229.
Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M,
Earl HM, Poole CJ, Hiller L, Dunn JA, et al. Association between
CD8+ T-cell infiltration and breast cancer survival in 12 439
patients. Ann Oncol. 2014;25(8):1536–1543. doi:10.1093/annonc/
mdu191.
Shou J, Zhang Z, Lai Y, Chen Z, Huang J. Worse outcome in breast
cancer with higher tumor-infiltrating FOXP3+ Tregs: a systematic
review and meta-analysis. BMC Cancer. 2016;16(1):687.
doi:10.1186/s12885-016-2732-0.
Chafe SC, Riaz N, Burugu S, Gao D, Leung SCY, Lee AF, Lee C-H,
Dedhar S, Nielsen TO. Granulocyte colony stimulating factor
expression in breast cancer and its association with carbonic anhy
drase ix and immune checkpoints. Cancers 2021;13(5):1–21.
doi:10.3390/cancers13051022.
Asleh K, Lyck Carstensen S, Tykjær Jørgensen CL,
Burugu S, Gao D, Won JR, Jensen M-B, Balslev E,
Lænkholm A-V, Nielsen DL, et al. Basal biomarkers nestin
and INPP4B predict gemcitabine benefit in metastatic
breast cancer: samples from the phase III SBG0102 clinical
trial. Int J Cancer. 2019;144(10):2578–2586. doi:10.1002/
ijc.31969.
Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK,
Perou CM, Nielsen TO. Basal-like breast cancer defined by five
biomarkers has superior prognostic value than triple-negative
phenotype. Clin Cancer Res. 2008;14(5):1368–1376. doi:10.1158/
1078-0432.CCR-07-1658.
Cheang MCU, Treaba DO, Speers CH, Olivotto IA,
Bajdik CD, Chia SK, Goldstein LC, Gelmon KA,
Huntsman D, Gilks CB, et al. Immunohistochemical detec
tion using the new rabbit monoclonal antibody SP1 of
estrogen receptor in breast cancer is superior to mouse
monoclonal antibody 1D5 in predicting survival. J Clin
Oncol.
2006;24(36):5637–5644.
doi:10.1200/
JCO.2005.05.4155.
Chia S, Norris B, Speers C, Cheang M, Gilks B, Gown AM,
Huntsman D, Olivotto IA, Nielsen TO, Gelmon K, et al. Human
epidermal growth factor receptor 2 overexpression as a prognostic
factor in a large tissue microarray series of node-negative breast
cancers. J Clin Oncol. 2008;26(35):5697–5704. doi:10.1200/
JCO.2007.15.8659.
Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8
+lymphocyte infiltration is an independent favorable prognostic
indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):
R48. doi:10.1186/bcr3148.
Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, BagoHorvath Z, Bane A, Bedri S, Brock J, et al. Standardized evaluation
of tumor-infiltrating lymphocytes in breast cancer: results of the
ring studies of the international immuno-oncology biomarker
working group. Mod Pathol. 2016;29(10):1155–1164. doi:10.1038/
modpathol.2016.109.
Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S,
Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N,
Nielsen TO, et al. Prognostic significance of macrophage infiltra
tion in leiomyosarcomas. Clin Cancer Res. 2008;14(5):1423–1430.
doi:10.1158/1078-0432.CCR-07-1712.
Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. LAG-3+ tumor
infiltrating lymphocytes in breast cancer: clinical correlates and
association with PD-1/PD-L1+ tumors. Ann Oncol. 2017;28
(12):2977–2984. doi:10.1093/annonc/mdx557.
Liu S, Foulkes WD, Leung S, Gao D, Lau S, Kos Z, Nielsen TO.
Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes
in breast cancer depends on estrogen receptor and human epider
mal growth factor receptor-2 expression status and concurrent

49.

50.

51.

52.

53.

54.

55.
56.

57.

58.

59.

60.

61.

62.

cytotoxic T-cell infiltration. Breast Cancer Res. 2014;16(5):432.
doi:10.1186/s13058-014-0432-8.
VENTANA PD-L1 (SP142) assay interpretation guide for
triple-negative breast carcinoma (TNBC). [accessed 20 Oct 2020.
https://diagnostics.roche.com/global/en/products/tests/ventanapd-l1-_sp142-assay1.html .
Liu S, Chen B, Burugu S, Leung S, Gao D, Virk S, Kos Z,
Parulekar WR, Shepherd L, Gelmon KA, et al. Role of cytotoxic
tumor-infiltrating lymphocytes in predicting outcomes in meta
static HER2-positive breast cancer a secondary analysis of
a randomized clinical trial. JAMA Oncol. 2017;3(11):e172085.
doi:10.1001/jamaoncol.2017.2085.
Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F,
Rouas G, Francis P, Crown JPA, Hitre E, et al. Prognostic and
predictive value of tumor-infiltrating lymphocytes in a phase III
randomized adjuvant breast cancer trial in node-positive breast
cancer comparing the addition of docetaxel to doxorubicin with
doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol.
2013;31(7):860–867. doi:10.1200/JCO.2011.41.0902.
Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D,
Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F, et al. CD4
+CD25+ regulatory T cells suppress tumor immunity but are
sensitive to cyclophosphamide which allows immunotherapy of
established tumors to be curative. Eur J Immunol. 2004;34
(2):336–344. doi:10.1002/eji.200324181.
Samanta D, Park Y, Ni X, Li H, Zahnow CA, Gabrielson E, Pan F,
Semenza GL. Chemotherapy induces enrichment of CD47+ /CD73
+ /PDL1+ immune evasive triple-negative breast cancer cells. Proc
Natl Acad Sci. 2018;115(6):E1239–E1248. doi:10.1073/
pnas.1718197115.
Tang M, Gao S, Zhang L, Liu B, Li J, Wang Z, Zhang W. Docetaxel
suppresses immunotherapy efficacy of natural killer cells toward
castration-resistant prostate cancer cells via altering androgen
receptor-lectin-like transcript 1 signals. Prostate 2020;80
(10):742–752. doi:10.1002/pros.23988.
Home - ClinicalTrials.gov. [accessed 2020 Oct 20]. https://clinical
trials.gov/ .
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J,
Denkert C, Park YH, Hui R, Harbeck N, et al. Pembrolizumab for
early triple-negative breast cancer. N Engl J Med. 2020;382
(9):810–821. doi:10.1056/NEJMoa1910549.
Schrijver WAME, Suijkerbuijk KPM, Van Gils CH, Van Der
Wall E, Moelans CB, Van Diest PJ. Receptor conversion in distant
breast cancer metastases: a systematic review and meta-analysis.
J Natl Cancer Inst. 2018;110(6):568–580. doi:10.1093/jnci/djx273.
Foukakis T, Lövrot J, Matikas A, Zerdes I, Lorent J, Tobin N,
Suzuki C, Brage SE, Carlsson L, Einbeigi Z, et al. Immune gene
expression and response to chemotherapy in advanced breast
cancer. Br J Cancer. 2018;118(4):480–488. doi:10.1038/
bjc.2017.446.
Szekely B, Bossuyt V, Li X, Wali VB, Patwardhan GA, Frederick C,
Silber A, Park T, Harigopal M, Pelekanou V, et al. Immunological
differences between primary and metastatic breast cancer. . Annals
of Oncology. 2018;29(11):2232–2239. doi:10.1093/annonc/
mdy399.
Rozenblit M, Huang R, Danziger N, Hegde P, Alexander B,
Ramkissoon S, Blenman K, Ross JS, Rimm DL, Pusztai L, et al.
Comparison of PD-L1 protein expression between primary tumors
and metastatic lesions in triple negative breast cancers.
J Immunother Cancer. 2020;8(2):e001558. doi:10.1136/jitc-2020001558.
Zhu L, Narloch JL, Onkar S, Joy M, Broadwater G, Luedke C,
Hall A, Kim R, Pogue-Geile K, Sammons S, et al. Metastatic breast
cancers have reduced immune cell recruitment but harbor
increased macrophages relative to their matched primary tumors.
J Immunother Cancer. 2019;7(1):265. doi:10.1186/s40425-0190755-1.
Emens LA, Molinero L, Loi S, Rugo HS, Schneeweiss A, Diéras V,
Iwata H, Barrios CH, Nechaeva M, Nguyen-Duc A, et al.
Atezolizumab and nab-paclitaxel in advanced triple-negative

ONCOIMMUNOLOGY

breast cancer: biomarker evaluation of the IMpassion130 study.
JNCI J Natl Cancer Inst. 2021:djab004. doi:10.1093/jnci/djab004.
63. Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B,
Christie M, Van De Vijver K, Estrada MV, Gonzalez-Ericsson PI,
et al. Assessing tumor-infiltrating lymphocytes in solid tumors:
a practical review for pathologists and proposal for

e1924492-11

a standardized method from the international immunooncology
biomarkers working group: part 1: assessing the host immune
response, tils in invasive breast carcinoma and ductal carcinoma
in situ, metastatic tumor deposits and areas for further research.
Adv
Anat
Pathol.
2017;24(5):235–251.
doi:10.1097/
PAP.0000000000000162.

